High-dose Wegovy debuts at $399 for self-paying patients
Paige Twenter / beckershospitalreview - Novo Nordisk’s recently approved high-dose Wegovy formulation has entered the U.S. market and is available for $399 per month for self-paying patients, the drugmaker said April 7. In March, the FDA approved Wegovy HD, a 7.2-mg injection of semaglutide, as…
AI Summary: Novo Nordisk has introduced a higher‑dose formulation of Wegovy (semaglutide) in the U.S., offering self‑pay patients access at a $399 monthly price. The rollout reflects growing demand for GLP‑1 therapies and fuels ongoing debates about affordability, access and how much of weight‑management care should depend on out‑of‑pocket spending.
- On scene: industry shifts, IPOs, stigma and miscellaneous reports (4)
- On site: Novo rolls out Wegovy HD, sparking access debates (7)
- Regulators press for more GLP-1 safety data and oversight (4)
- Reporting from clinics: GLP-1s vary in effect, risk muscle loss (9)
- All Other Stories
On scene: industry shifts, IPOs, stigma and miscellaneous reports
On site: Novo rolls out Wegovy HD, sparking access debates
Regulators press for more GLP-1 safety data and oversight
Reporting from clinics: GLP-1s vary in effect, risk muscle loss
All Other Stories
Related Stories
Novo Nordisk commits $2.1B to Vivtex to pursue oral obesity medicines / 4 months
Novo Nordisk legal action threat over copycat Wegovy pill / 5 months
Eli Lilly launches Employer Connect to broaden GLP‑1 coverage / 4 months
Lilly’s Zepbound bests Novo’s CagriSema in head‑to‑head obesity trial / 4 months
Novo Nordisk oral GLP‑1 pill clears FDA for obesity treatment / 6 months
Medicare GLP‑1 expansion spurs retailer programs and policy debate / 13 days
Lilly’s next‑gen GLP‑1 posts compelling Phase 3 weight and A1C results / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Pediatric Oncology, Hearing Loss, Olfaction, Health IT and look for the RSS link.
StackHealth Time Machine